CY1119510T1 - Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης - Google Patents

Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης

Info

Publication number
CY1119510T1
CY1119510T1 CY20171101131T CY171101131T CY1119510T1 CY 1119510 T1 CY1119510 T1 CY 1119510T1 CY 20171101131 T CY20171101131 T CY 20171101131T CY 171101131 T CY171101131 T CY 171101131T CY 1119510 T1 CY1119510 T1 CY 1119510T1
Authority
CY
Cyprus
Prior art keywords
agonist
methods
combination
antibody
antagonist
Prior art date
Application number
CY20171101131T
Other languages
English (en)
Inventor
Bryan BARNHART
Maria N. JURE-KUNKEL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1119510T1 publication Critical patent/CY1119510T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται μέθοδοι και συνθέσεις για θεραπεία καρκίνου χρησιμοποιώντας αποτελεσματική ποσότητα ανταγωνιστή PD-1 (π.χ., αντίσωμα) σε συνδυασμό με DR4 ή αγωνιστή DR5 (π.χ., αντίσωμα).
CY20171101131T 2013-03-14 2017-10-30 Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης CY1119510T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783184P 2013-03-14 2013-03-14
PCT/US2014/024208 WO2014159562A1 (en) 2013-03-14 2014-03-12 Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Publications (1)

Publication Number Publication Date
CY1119510T1 true CY1119510T1 (el) 2018-03-07

Family

ID=50483524

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101131T CY1119510T1 (el) 2013-03-14 2017-10-30 Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης

Country Status (15)

Country Link
US (3) US20160067337A1 (el)
EP (2) EP3305812B1 (el)
CY (1) CY1119510T1 (el)
DK (1) DK2970473T3 (el)
ES (2) ES2644022T3 (el)
HR (1) HRP20171758T1 (el)
HU (1) HUE035865T2 (el)
LT (1) LT2970473T (el)
ME (1) ME02917B (el)
NO (1) NO3080374T3 (el)
PL (1) PL2970473T3 (el)
PT (1) PT2970473T (el)
RS (1) RS56531B1 (el)
SI (1) SI2970473T1 (el)
WO (1) WO2014159562A1 (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
SI2970473T1 (sl) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250601A4 (en) 2015-01-26 2018-07-11 MacroGenics, Inc. Multivalent molecules comprising dr5-binding domains
MX2017011206A (es) 2015-03-04 2018-05-17 Merck Sharp & Dohme Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
MX2020008333A (es) * 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN111757941A (zh) * 2018-02-26 2020-10-09 Igm生物科学股份有限公司 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
BR112021007318A2 (pt) 2018-10-17 2021-08-31 Biolinerx Ltd. Tratamento de adenocarcinoma pancreático metastático
CN113365653A (zh) * 2019-01-18 2021-09-07 佐治亚大学研究基金会股份有限公司 盐纳米颗粒和组合物及其使用方法
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022081869A1 (en) * 2020-10-14 2022-04-21 University Of Virginia Patent Foundation Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1763223A (en) 1927-04-02 1930-06-10 Owens Illinois Glass Co Glassware-annealing leer
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
JP4435304B2 (ja) 1995-06-29 2010-03-17 イミュネックス・コーポレーション アポトーシスを誘導するサイトカイン
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
EP0904366A1 (en) 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
JP4330180B2 (ja) 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
JP2002512515A (ja) 1997-04-16 2002-04-23 ミレニアム ファーマシューティカルズ インク． 腫瘍壊死因子受容体関連蛋白質ＴＡＮＧＯ−６３ｄおよびＴＡＮＧＯ−６３ｅ
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DE69838249T3 (de) 1997-05-15 2012-01-19 Genentech, Inc. Anti-apo-2 antikörper
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
CA2293740A1 (en) 1997-06-18 1998-12-23 Genentech, Inc. Apo-2dcr, a tnf-related receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999009165A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
AU4817200A (en) 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
WO2000067793A1 (en) 1999-05-06 2000-11-16 Human Genome Sciences, Inc. Death domain containing receptor 4
ATE324377T1 (de) 1999-05-28 2006-05-15 Human Genome Sciences Inc Fc-fusionsproteine des menschlichen tumor-nekrose-faktor-rezeptors tr10
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003054216A2 (en) 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1534336A4 (en) 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
CN102317314A (zh) 2008-10-10 2012-01-11 阿纳福公司 结合trail-r1和trail-r2的多肽
PL2483310T3 (pl) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecyficzne przeciwciała agonistyczne dla receptora śmierci
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
JP2013528599A (ja) 2010-05-14 2013-07-11 アムジェン インコーポレイテッド 増強デスレセプター・アゴニスト
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
EP2968294B1 (en) 2013-03-13 2019-05-01 Oncoceutics, Inc. 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer
SI2970473T1 (sl) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
ES2941895T3 (es) * 2014-11-25 2023-05-26 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III)
EP3595720A4 (en) * 2017-03-14 2021-05-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT AN ACID PH
CN113056483A (zh) * 2018-07-09 2021-06-29 戊瑞治疗有限公司 结合到ilt4的抗体

Also Published As

Publication number Publication date
HRP20171758T1 (hr) 2017-12-29
NO3080374T3 (el) 2018-03-24
US20220098302A1 (en) 2022-03-31
SI2970473T1 (sl) 2017-10-30
EP3305812B1 (en) 2020-06-17
RS56531B1 (sr) 2018-02-28
WO2014159562A1 (en) 2014-10-02
EP2970473A1 (en) 2016-01-20
PL2970473T3 (pl) 2018-01-31
PT2970473T (pt) 2017-10-26
EP2970473B1 (en) 2017-08-16
ME02917B (me) 2018-10-20
ES2644022T3 (es) 2017-11-27
US11103579B2 (en) 2021-08-31
US20160067337A1 (en) 2016-03-10
HUE035865T2 (en) 2018-05-28
ES2812208T3 (es) 2021-03-16
EP3305812A1 (en) 2018-04-11
US20180360962A1 (en) 2018-12-20
DK2970473T3 (da) 2017-11-27
LT2970473T (lt) 2017-10-25

Similar Documents

Publication Publication Date Title
CY1119510T1 (el) Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1124955T1 (el) Pd-1 αντισωματα
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
BR112015032224A2 (pt) anticorpos anti-fcrh5
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates